Brief: Tenaya Therapeutics Receives Positive Safety Reviews From Independent Dsmbs To Advance Both TN-201 And TN-401 Gene Therapy Clinical Trials As Designed
30/07/2025 14:26
July 30 (Reuters) - Tenaya Therapeutics Inc TNYA.O: TENAYA RECEIVES POSITIVE SAFETY REVIEWS FROM INDEPENDENT DSMBS TO ADVANCE BOTH TN-201 AND TN-401 GENE THERAPY CLINICAL TRIALS AS DESIGNED TENAYA THERAPEUTICS INC: PLANS TO REPORT LONGER-TERM FOLLOW-UP DATA FROM COHORT 1 AND INITIAL DATA FROM COHORT 2 IN Q4 OF THIS YEAR Source text: ID:nGNX6cPvmZ Further company coverage: TNYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027